R. Kate (Katie) Kelley, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
R. Kate (Katie) Kelley, MD

Associate Professor of Clinical Medicine, Department of Medicine (Hematology/Oncology), UCSF

Phone: (415) 353-9888 (appts)
Box 1770, UCSF
San Francisco, CA 94143-1770

View on UCSF Profiles

Cancer Center Membership

Program Member » Developmental Therapeutics

Research Summary

My research focuses on the early development of new treatments and biomarkers in hepatocellular carcinoma (HCC) and cancers of the biliary tract. I currently am the Study Chair for two multicenter investigator-initiated clinical trials and serve as the site PI for seven industry-sponsored clinical trials of novel therapeutic agents or combinations in advanced hepatobiliary cancer patients. I have leadership roles as a member of the Steering Committee for a large, multinational randomized phase III trial and as a member of Safety Review Team for a multicenter phase I trial. Based upon our clinical expertise and patient population, we have consistently achieved high accrual to these studies and have a robust pipeline of new clinical trials in development.

As a foundation for future translational and epidemiology research in this complex and biologically heterogeneous family of cancers, I initiated the UCSF Hepatobiliary Tissue Bank and Registry (HBTBR, CC#124512) in 2012 with philanthropic funding. This bank and registry collects fresh and archival tumor tissue samples as well as blood samples along with longitudinal clinical data from patients with hepatobiliary cancers who receive cancer care at UCSF. This bank has enrolled over 200 cases since late 2012 and has already contributed samples and/or data to multiple projects, including: the NCI/NHGRI The Cancer Genome Atlas (TCGA) liver and cholangiocarcinoma cohorts; patient-derived xenografting and cell line development in the Bardeesy Lab at Harvard Medical School; a pilot project of next-generation tumor sequencing in advanced HCC archival samples from patients treated with sorafenib; two large consortium genome-wide association studies led by MD Anderson Cancer Center (PI: Hassan, R01CA186566) and the Mayo Clinic (PI: Lewis Roberts); and two multicenter, retrospective analyses of clinical outcomes in cholangiocarcinoma patients according to molecular subtype, in collaboration with MD Anderson Cancer Center and Sheba University, Israel.

Education

Harvard College, Boston, MA, B.A., 1993-97, Biochemistry
UCLA, M.D., 1998-2002, Medicine
UCLA, Intern, 2002-03, Medicine
UCLA, Resident, 2003-05, Medicine
UCLA, Chief Resident, 2005-06, Medicine
UCSF, Fellow, 2006-09, Hematology/Oncology


Professional Experience

  • 2005-2006
    University of California, Los Angeles, Clinical Instructor, Medicine
  • 2010-2016
    University of California, San Francisco, Health Sciences Assistant Clinical Professor of Medicine
  • 2010-2012
    San Francisco Veteran's Administration Medical Center, Staff Physician
  • 2016-present
    University of California, San Francisco, Health Sciences Associate Professor of Clinical Medicine

Honors & Awards

  • 1993-1997
    Harvard College Scholarship, Harvard College
  • 1993-1997
    Elizabeth Cary Agassiz Merit Award, Harvard College
  • 1997-1998
    Rotary Ambassadorial Scholarship, Costa Rica
  • 2001
    Alpha Omega Alpha, UCLA School of Medicine
  • 2001
    Merck Book Award, UCLA School of Medicine
  • 2001
    Janet M. Glascow Memorial Achievement Citation, American Medical Women's Association
  • 2004, 2006
    Solomon Scholars Resident Research Day Award, UCLA Department of Medicine
  • 2006
    Medical Student Teaching Award, UCLA Department of Medicine
  • 2009
    ASCO Cancer Foundation Merit Award, Gastrointestinal Cancers Symposium
  • 2010
    ASCO Young Investigator Award

Selected Publications

  1. Adjuvant sorafenib for liver cancer: wrong stage, wrong dose. Lancet Oncol. 2015 Oct; 16(13):1279-81.
    View on PubMed
  2. A MULTICENTER, OPEN-LABEL PHASE II CLINICAL TRIAL OF COMBINED MEK PLUS EGFR INHIBITION FOR CHEMOTHERAPY-REFRACTORY ADVANCED PANCREATIC ADENOCARCINOMA. Clin Cancer Res. 2015 Aug 6.
    View on PubMed
  3. Biliary Tract Cancers: Finding Better Ways to Lump and Split. J Clin Oncol. 2015 Aug 20; 33(24):2588-90.
    View on PubMed
  4. A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma. Cancer. 2015 Oct 1; 121(19):3481-90.
    View on PubMed
  5. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov. 2015 Oct; 5(10):1040-8.
    View on PubMed
  6. Cases of spontaneous tumor regression in hepatobiliary cancers: implications for immunotherapy? J Gastrointest Cancer. 2015 Jun; 46(2):161-5.
    View on PubMed
  7. Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls. BMC Cancer. 2015; 15(1):206.
    View on PubMed
  8. Challenges of coverage policy development for next-generation tumor sequencing panels: experts and payers weigh in. J Natl Compr Canc Netw. 2015 Mar; 13(3):311-8.
    View on PubMed
  9. A Case Series of Patients with HER2-Overexpressed Primary Metastatic Gastroesophageal Adenocarcinoma. Anticancer Res. 2014 Dec; 34(12):7357-60.
    View on PubMed
  10. Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model. Int J Cancer. 2015 Apr 15; 136(8):1967-75.
    View on PubMed
  11. Hepatobiliary cancers, version 2.2014. J Natl Compr Canc Netw. 2014 Aug; 12(8):1152-82.
    View on PubMed
  12. Genomic sequencing: assessing the health care system, policy, and big-data implications. Health Aff (Millwood). 2014 Jul; 33(7):1246-53.
    View on PubMed
  13. 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study. J Gastrointest Cancer. 2014 Jun; 45(2):168-80.
    View on PubMed
  14. A review of hepatocellular carcinoma (HCC) staging systems. Chin Clin Oncol. 2013 Dec; 2(4):33.
    View on PubMed
  15. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer. 2013 Oct 1; 109(7):1725-34.
    View on PubMed
  16. Brivanib and FOLFOX in hepatocellular carcinoma: finding the common themes among negative trials. J Clin Oncol. 2013 Oct 1; 31(28):3483-6.
    View on PubMed
  17. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. Ann Oncol. 2013 Jul; 24(7):1900-7.
    View on PubMed
  18. Novel therapeutics in hepatocellular carcinoma: how can we make progress? Am Soc Clin Oncol Educ Book. 2013.
    View on PubMed
  19. Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium. Gastrointest Cancer Res. 2013 Jan; 6(1):3-9.
    View on PubMed
  20. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. Am J Clin Oncol. 2012 Oct; 35(5):411-7.
    View on PubMed

Go to UCSF Profiles, powered by CTSI